Inflammatory bowel disease and bladder cancer risk: based on a Mendelian randomization study

BMC Urology

Table 3 Sensitivity analysis of the causal association between IBD and BC

Exposure	Outcome		Heterogeneity		Horizontal pleiotropy
			Cochran Q statistic		MR-Egger		MR–PRESSO (Outlier-corrected)
		IVW Q	IVW I²	IVW P^#	Egger intercept	P^#value	Outlier	P^* for global test
Training set	UKBB
IBD	BC	147.9	15.48	0.08	-0.004	0.5	“rs7608910”,“rs1569328”	0.07
CD		131.2	14.6	0.1	-0.002	0.74	“rs1569328”,“rs7608910”	0.11
UC		90.3	8.11	0.27	-0.006	0.43	0	0.26
Validation set	Finngen
IBD	BC	131.4	6.45	0.28	-0.008	0.3	0	0.27
CD		119.8	5.74	0.31	-0.006	0.51	0	0.3
UC		71.1	0	0.6	0.003	0.72	“rs12132349”,“rs36070529”,“rs4795397”,“rs9271255”	0.6

* MR analysis using IVW method after removing outliers identified by MR-PRESSO method
# Heterogeneity test after removing outliers
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; BC, bladder cancer; IVW, inverse variance weighted; OR, odds ratio; CI, confidence interval; SE, standard error

ISSN: 1471-2490